S.M.A.I.O S.A. (EPA:ALSMA)

Market Cap	37.51M -3.3%
Revenue (ttm)	9.16M +66.7%
Net Income	-2.23M
EPS	-0.41
Shares Out	5.63M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	26
Open	6.76
Previous Close	6.76
Day's Range	6.66 - 6.76
52-Week Range	5.90 - 9.10
Beta	0.54
Analysts	Buy
Price Target	8.20 (+23.12%)
Earnings Date	Oct 13, 2026

About S.M.A.I.O

S.M.A.I.O S.A. provides software, implantable devices, and associated services for the surgical treatment of spinal deformities. It offers solutions for surgeons, including programs for training, assistance with surgical planning based on KEOPS database. The company also offers solutions, such as i-PLAN platform, a surgical planning solution; i-PERFORM, an assisted execution of the surgical procedure based point by point on the sheet; i-CHECK to measure and monitor the final result based on a data management platform; and i-LEARN, a platform to...

• Industry: Health Information Services
• Sector: Healthcare
• Founded: 2009
• Employees: 45
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALSMA

Financial Performance

In 2025, S.M.A.I.O's revenue was 9.16 million, an increase of 66.67% compared to the previous year's 5.50 million. Losses were -2.23 million, -5.11% less than in 2024.

Analyst Summary

According to 2 analysts, the average rating for ALSMA stock is "Buy." The 12-month stock price target is €8.20, which is an increase of 23.12% from the latest price.

Price Target

€8.20

(23.12% upside)

Analyst Consensus: Buy

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Oct 3, 2026

Data Sources Report a data error